scholarly journals Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells

2022 ◽  
Vol 15 (1) ◽  
pp. 101265
Author(s):  
Nayanendu Saha ◽  
Kai Xu ◽  
Zhongyu Zhu ◽  
Dorothea Robev ◽  
Teja Kalidindi ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cancer Cells ◽  
Antibody Targeting

Abstract B37: Development of a monoclonal antibody targeting xCT/SLC7A11 expressed in metastatic cancer cells

2020 ◽  
Author(s):  
Ahmad Salameh ◽  
Jerri Caldeira ◽  
Valeria Rolih ◽  
Elisabetta Bolli ◽  
Laura Conti ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cancer Cells ◽  
Metastatic Cancer ◽  
Antibody Targeting ◽  
Metastatic Cancer Cells

scholarly journals Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting

RSC Advances ◽  
2021 ◽  
Vol 11 (26) ◽  
pp. 16131-16141
Author(s):  
Manali Haniti Mohd-Zahid ◽  
Siti Nadiah Zulkifli ◽  
Che Azurahanim Che Abdullah ◽  
JitKang Lim ◽  
Sharida Fakurazi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Gold Nanoparticles ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Chemotherapeutic Agent ◽  
Cell Targeting ◽  
Specific Targeting ◽  
Colorectal Cancer Cells ◽  
Cancer Cell Targeting

5-FU-PEGylated AuNPs-CD133 is designed to improve specific targeting of 5-FU against colorectal cancer cells which abundantly express CD133.

Hair Growth in a Patient with Alopecia Areata on Tocilizumab

2021 ◽  
pp. 1-5
Author(s):  
Chloe J. Walker ◽  
Kelly E. Flanagan ◽  
James T. Pathoulas ◽  
Isabel Pupo Wiss ◽  
Maryanne M. Senna
Keyword(s):  
Monoclonal Antibody ◽  
Autoimmune Disease ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Interleukin 6 ◽  
Hair Growth ◽  
Posterior Uveitis ◽  
Case Presentation ◽  
Antibody Targeting ◽  
Growth Changes

<b><i>Introduction:</i></b> Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. <b><i>Case Presentation:</i></b> Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. <b><i>Discussion:</i></b> Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.

Sign in / Sign up

Export Citation Format

Share Document